author-photo

Heather Kostner

Seattle Genetics

11

Papers

472

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies

2017 Blood
Show All
- Source
- Cite
- Save
Citations (18)
SGN-CD19B, a Pyrrolobenzodiazepine (PBD)-Based Anti-CD19 Drug Conjugate, Demonstrates Potent Preclinical Activity Against B-Cell Malignancies

2015 Blood
Show All
- Source
- Cite
- Save
Citations (3)
SGN–LIV1A: A Novel Antibody–Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer

2014 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (64)
Abstract 3962: SGN-LIV1A: a development stage antibody drug-conjugate targeting LIV-1 for the treatment of metastatic breast cancer.

2013 Cancer Research
Show All
- Source
- Cite
- Save
Citations (3)
SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

2013 Blood
Show All
- Source
- Cite
- Save
Citations (304)
Abstract 4630: Integrin αVα6 is expressed on multiple solid tumors and is a potential therapeutic target for auristatin-based antibody-drug conjugates

2012 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75

2010 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (60)
Abstract #4652: CD70 expression in multiple types of carcinomas: new targets for auristatin-based anti-CD70 antibody-drug conjugate, SGN-75

2009 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)